Global Apheresis Market 2023-2030

Description

List of Tables

Title: Global Apheresis Market Size, Share & Trends Analysis Report by Product (Apheresis Disposables, Apheresis Devices), by Procedure (Automated blood collection, Therapeutic Apheresis), and by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis)Forecast Period (2023-2030).

The global apheresis market is anticipated to grow at a CAGR of 8.4% during the forecast period (2023-2030). The market's growth is attributed to the ongoing innovation in medical technology across the globe. Apheresis systems such as Spectra Optia provide innovative and effective treatment alternatives, increasing usage globally. In a therapeutic treatment known as RBCX, the patient's own red blood cells-often sick or defective cells-are removed and replaced with healthy donor red blood cells. Treatment for diseases like sickle cell anemia and other hemoglobinopathies, in addition to therapy for other autoimmune disorders, frequently involves surgical procedures. Accordingly, market players are coming up with new products to cater the demand for automated red blood cell exchange treatment. For instance, in June 2022, NHS England in the UK has chosen the automated red blood cell exchange (RBCX) treatment carried out on the company's Spectra Optia Apheresis System to treat sickle cell disease. This choice led to a wider deployment of Spectra Optia in hospitals throughout England.

Segmental Outlook

The global apheresis market is segmented on the product, procedure, and application. Based on the product, the market is sub-segmented into apheresis disposables, apheresis devices, centrifugal apheresis devices, and membrane separation devices. Based on the procedure, the market is sub-segmented into automated blood collection, therapeutic apheresis, therapeutic apheresis disposables, and therapeutic apheresis devices. Further, on the basis of application, the market is sub-segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, and photopheresis. Among the application, the photospheres is sub-segment is anticipated to hold a considerable share of the market owing to the growing demand for photopheresis in organ transplant rejection therapies and increased prevalence of blood diseases.

The Plateletpheresis Sub-Segment is Anticipated to Hold a Considerable Share of the Global Apheresis Market

Among the application, the plateletpheresis sub-segment is expected to hold a considerable share of the global apheresis market. The segmental growth is attributed to the rising prevalence of chronic diseases around the globe. Treatment for a variety of chronic diseases, such as autoimmune disorders, neurological issues, and some malignancies, sometimes involves apheresis operations. Apheresis operations are in higher demand as the illnesses become more prevalent. According to the National Institute of Health (NIH), in September 2022, out of the 7,478 donors that were examined for plateletpheresis, 3,232 (43.2%) had delays, with 3,089 (42.5%) men and 142 (63.1%) women donors. 96.5% of extensions have been temporary. Low hemoglobin (Hb) (7.2%) and low venous access (22.4% and 47.4%, respectively, are among them. 24.7% (58 out of 234) of the donors that received a decline owing to the low Hb had a Hb between 12.0% and 12.4 %. The current donor selection criteria opened to a minimum Hb of 12 g/dl and minimum platelet count of 140 103/l, there is potential to increase the number of eligible plateletpheresis donors.

Regional Outlook

The global apheresis market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the high population density with an increase in senior citizen population.

The North America Region is Expected to Grow at a Significant CAGR in the Global Apheresis Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Manufacturers of automated blood collection and information systems in addition to other apheresis technology suppliers report growing demand for the products and services they supply. According to National Institute of Health (NIH), in March 2022, fixed sites increased total apheresis procedures by 37.0% and increased turns per bed by 46.0% as a result of the cancellation of mobile blood drives; however, less products were obtained per donor. Platelet expiration rate went from 6.8% (pre-pandemic) to less than 4.0% by simply obtaining the amount required. Donor frequency, that is used to measure donor involvement, went from 1.6 in January 2020 to 1.8 in March 2021. The blood center increased donor involvement and avoided accumulating an excess of simply specific kind of blood product throughout the epidemic by utilizing technology advancements such as automated blood collection and information systems.

Market Players Outlook

The major companies serving the global apheresis market include Cerus Corp., Crown Bioscience, Inc., Fresenius SE & Co. KGaA, Haemonetics, Kaneka Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2022, Terumo Blood and Cell Technologies, and Eliaz Therapeutics Inc. (ETI), collaborated to optimize the selective removal of an upstream inflammatory protein termed Galectin-3 (Gal-3) from blood plasma to help treat AKI and S-AKI.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global apheresis market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027669

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Asahi Kasei Corp.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. B. Braun SE
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Baxter International, Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Apheresis Market by Product
- 4.1.1. Apheresis Disposables
- 4.1.2. Apheresis Devices
4.2. Global Apheresis Market by Procedure
- 4.2.1. Automated Blood Collection (Donor Apheresis)
- 4.2.2. Therapeutic Apheresis
4.3. Global Apheresis Market by Application
- 4.3.1. Plasmapheresis
- 4.3.2. Plateletpheresis
- 4.3.3. Erythrocytapheresis
- 4.3.4. Leukapheresis
- 4.3.5. Photopheresis

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Cerus Corp.
6.2. Crown Bioscience, Inc.
6.3. Fresenius SE & Co. KGaA
6.4. Haemonetics
6.5. Kaneka Corp.
6.6. Macopharma
6.7. Nikkiso Co., Ltd.
6.8. Otsuka Holdings Co., Ltd.
6.9. SB-KAWASUMI LABORATORIES, INC.
6.10. Terumo BCT
6.11. Toray Medical Co., Ltd.